US20200015760A1 - Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems - Google Patents
Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems Download PDFInfo
- Publication number
- US20200015760A1 US20200015760A1 US16/577,719 US201916577719A US2020015760A1 US 20200015760 A1 US20200015760 A1 US 20200015760A1 US 201916577719 A US201916577719 A US 201916577719A US 2020015760 A1 US2020015760 A1 US 2020015760A1
- Authority
- US
- United States
- Prior art keywords
- glucose
- insulin
- user
- time
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title claims abstract description 115
- 229940125396 insulin Drugs 0.000 title claims abstract description 58
- 102000004877 Insulin Human genes 0.000 title claims abstract description 57
- 108090001061 Insulin Proteins 0.000 title claims abstract description 57
- 238000012417 linear regression Methods 0.000 title claims description 10
- 238000000034 method Methods 0.000 title abstract description 24
- 206010022489 Insulin Resistance Diseases 0.000 title description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 82
- 239000008103 glucose Substances 0.000 claims abstract description 82
- 230000004044 response Effects 0.000 claims abstract description 23
- 235000014633 carbohydrates Nutrition 0.000 claims abstract description 18
- 230000006870 function Effects 0.000 claims description 15
- 102000016261 Long-Acting Insulin Human genes 0.000 claims description 12
- 108010092217 Long-Acting Insulin Proteins 0.000 claims description 12
- 229940100066 Long-acting insulin Drugs 0.000 claims description 12
- 108010026951 Short-Acting Insulin Proteins 0.000 claims description 10
- 229940123958 Short-acting insulin Drugs 0.000 claims description 10
- 201000001421 hyperglycemia Diseases 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 8
- 230000001419 dependent effect Effects 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 238000013178 mathematical model Methods 0.000 claims 7
- 238000007726 management method Methods 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 150000001720 carbohydrates Chemical class 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 208000013016 Hypoglycemia Diseases 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 238000005316 response function Methods 0.000 description 5
- 230000009230 endogenous glucose production Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940029980 drug used in diabetes Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 239000012731 long-acting form Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/74—Details of notification to user or communication with user or patient ; user input means
- A61B5/742—Details of notification to user or communication with user or patient ; user input means using visual displays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
Definitions
- the present invention relates to a method for predicting the glucose concentration of a subject and recommending therapeutic action.
- Patients on MDI maintain a healthy glucose level by typically taking five to ten injections per day. These may include injection of a long-acting form of insulin before going to sleep and/or after waking, as well as short-acting insulin injections both before and after every meal and snack, with those following meals chosen to correct for prior insufficient doses.
- most diabetics today monitor their blood glucose with small blood draws from a finger prick before each injection.
- An increasing number of diabetics also monitor their glucose using a continuous glucose monitor (CGM), which provides glucose readings with much higher frequency, commonly around once every five minutes.
- An “artificial pancreas” is a heavily researched future treatment device for diabetes that uses a closed loop between a CGM and an insulin pump. Given frequent, accurate readings from a CGM, the insulin pump should be able to determine, without human intervention, how much insulin to give. This will require the development of an algorithm that can precisely calculate the response of blood glucose to insulin.
- Previous inventions in the field of glucose prediction have used the time-series of glucose over a narrow window in the recent past, possibly around 30 minutes, to predict glucose over a similar time frame in the future, without directly accounting for external factors like insulin, dietary carbohydrates, and exercise.
- the previous inventions also often focus on making universal predictions of insulin response that are not individualized to each patient and they predict a single, time-integrated response rather than response as a function of time.
- This patent is for a linear regression-based method to learn a user's blood glucose response to short-acting insulin, long-acting insulin, dietary carbohydrates, and lifestyle factors such as exercise.
- This method learns a unique response for each user.
- the calculated response curve is a function of time, not merely the total time-integrated effect of 1 unit of a given factor.
- this method determines optimal insulin dosages in response to the user's relevant activities. This separate step allows the method to assign an asymmetrical cost function for hyperglycemia and hypoglycemia.
- the two steps learning the user's response curves and suggesting the optimal insulin dose, can be decoupled.
- the time dependent response curves can be integrated to determine the cumulative effect of each kind of insulin and dietary carbohydrates.
- the insulin:carb ratio can then be calculated as the total effect of 1 unit of insulin divided by the total effect of 1 carbohydrate.
- clinically averaged response functions from many patients, in combination with the user's weight can be used as an approximate input for the second step, determining the optimal insulin dose.
- FIG. 1 is a flow diagram depicting the input and output to the two stages of the process of determining individualized insulin sensitivity and optimal insulin dose.
- Step 1 of the method linearly regresses changes in glucose over possibly overlapping time intervals onto the following equation:
- step 1 of the method could fit glucose changes to the following equation:
- the length of the time periods for the response curves in step 1 is chosen such that the rate of change of glucose to that factor has an insignificant fluctuation over the time period.
- the number of time periods to look back from each g i which could be different for each factor—is chosen such that the number of periods multiplied by the length of each period is longer than the time for the insulin, carbohydrate, or exercise to clear the body. Endogeneous glucose production could also be set as a separate factor for different times of day, possibly blocks of one to six hours.
- step 2 the method could use the response functions learned in step 1 to suggest appropriate insulin doses.
- the output could be carbohydrate ratios, correction doses, and long-acting insulin doses for a user on MDI, or basal and bolus rates for CSII, to be programmed manually in an existing open-loop pump system or to be set automatically in a future, closed-loop artificial pancreas.
- the method takes the actual time series of food and exercise and combines them with the times, but not the sizes, of actual insulin doses, as well as the response functions to these factors learned in step 1. The method then calculates optimal insulin doses for each relevant event, where the ideal dose is the one that minimizes a cost function that penalizes hyperglycemia and hypoglycemia.
- the cost function for excursions outside the optimal glucose range could be asymmetrical in order to avoid hypoglycemia more strongly than hyperglycemia.
- the method can be used to suggest a best insulin:carb ratio.
- the method can suggest the proper correction dose for different levels of hyperglycemia.
- Step 2 will also assume that a fixed amount of long-acting insulin is taken each day, and it can suggest its ideal dose and time of application.
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 14/947,347, filed Nov. 20, 2015, pending, which application claims the benefit of Provisional Patent Application Ser. No. 62/083,191, filed Nov. 22, 2014, and titled “Method to Determine Individualized Insulin Sensitivity and Optimal Insulin Dose by Linear Regression,” the disclosure of each of which is hereby incorporated herein in its entirety by this reference. This invention was not made with any government support and the government has no rights in this invention.
- The present invention relates to a method for predicting the glucose concentration of a subject and recommending therapeutic action.
- In the United States, approximately three million people have type 1 diabetes.[1] To treat their condition, these patients depend either on multiple daily injections (MDI) of insulin or continuous subcutaneous insulin injection (CSII) by insulin pumps. Another 26 million people in the United States suffer from type 2 diabetes, many of whom become insulin dependent. In total, nearly six million Americans depend on insulin.[2] For these patients, choosing the correct dose and type of insulin to take, and when to take it, remains a significant challenge. The goal of an insulin regimen is to maintain blood glucose concentration within a narrow range. Chronically high glucose levels, hyperglycemia, leads to severe health problems and premature death. Acute low glucose levels, hypoglycemia, can cause fainting, seizures, and death. Patients on MDI maintain a healthy glucose level by typically taking five to ten injections per day. These may include injection of a long-acting form of insulin before going to sleep and/or after waking, as well as short-acting insulin injections both before and after every meal and snack, with those following meals chosen to correct for prior insufficient doses. In order to make informed dosage decisions, most diabetics today monitor their blood glucose with small blood draws from a finger prick before each injection. An increasing number of diabetics also monitor their glucose using a continuous glucose monitor (CGM), which provides glucose readings with much higher frequency, commonly around once every five minutes. Although it has already been appreciated that this high frequency data can be used to alert users to problematic glucose levels as they arise, the wealth of data provided by these machines has, so far, been underutilized for the challenge of determining optimal insulin doses.
- An “artificial pancreas” is a heavily researched future treatment device for diabetes that uses a closed loop between a CGM and an insulin pump. Given frequent, accurate readings from a CGM, the insulin pump should be able to determine, without human intervention, how much insulin to give. This will require the development of an algorithm that can precisely calculate the response of blood glucose to insulin.
- Previous inventions in the field of glucose prediction have used the time-series of glucose over a narrow window in the recent past, possibly around 30 minutes, to predict glucose over a similar time frame in the future, without directly accounting for external factors like insulin, dietary carbohydrates, and exercise. The previous inventions also often focus on making universal predictions of insulin response that are not individualized to each patient and they predict a single, time-integrated response rather than response as a function of time.
- U.S. Patent Publication No. 2011/0160555 to Reifman, published Jun. 30, 2011, for “Universal models for predicting glucose concentration in humans” “utilizes similarities in the short-term (30 minutes or less) dynamics of glucose regulation in different diabetic individuals to develop a single, universal autoregressive (AR) model for predicting future glucose levels across different patients.” This patent does not account for external factors that cause changes in glucose or attempt to learn individualized models for different patients. Similarly, U.S. Pat. No. 9,076,107, issued Jul. 7, 2015, to Cameron et al. for “Neural network for glucose therapy recommendation” uses recent glucose trends to predict future glucose trends, with the model trained on data from multiple patients rather than individualized. U.S. Pat. No. 7,695,434, issued Apr. 13, 2010, to Malecha for “Medical device for predicting a user's future glycemic state” uses CGM data to predict future glycemic state using a Hidden Markov Model and not linear regression. This method does not use information other than the time series of glucose before the moment of prediction to predict future glucose.
- U.S. Pat. No. 7,404,796, issued Jul. 29, 2008, to Ginsberg for “System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor” is a method for finding individualized carbohydrate-to-insulin ratios (CIRs) and insulin sensitivity factors (ISFs). At its greatest level of detail, that method gives the integrated effect of a unit of insulin or a carbohydrate on a user's glucose concentration, and not the effect as a function of time. That method also does not use linear regression.
- U.S. Patent Publication No. 2014/0073892, published Mar. 13, 2014, to Jette Randloev et al., for “Glucose predictor based on regularization networks with adaptively chosen kernels and regularization parameters” describes a method for predicting glucose based on data sets that are sparsely sampled in time, which does not make use of the glucose time series data made available by CGMs and the insulin time series data made available by insulin pumps. That method uses regularization networks with adaptively chosen kernels and regularization parameters and not linear regression.
- This patent is for a linear regression-based method to learn a user's blood glucose response to short-acting insulin, long-acting insulin, dietary carbohydrates, and lifestyle factors such as exercise. This method learns a unique response for each user. The calculated response curve is a function of time, not merely the total time-integrated effect of 1 unit of a given factor. After obtaining these response functions, in a second step, this method determines optimal insulin dosages in response to the user's relevant activities. This separate step allows the method to assign an asymmetrical cost function for hyperglycemia and hypoglycemia. This asymmetry is necessary because a positive fluctuation that results in only mild hyperglycemia and no immediate problems could, if only the sign of the fluctuation were reversed, cause severe hypoglycemia and death: Including this information in the same step as learning the user's response to insulin and carbohydrates would distort the user's true response. From the time series of a given user's glucose, insulin, exercise, and carbohydrate intake, the method learns the optimal dose and time of long-acting insulin, the optimal ratio of short-acting insulin to dietary carbohydrates, the optimal correction dose of short-acting insulin for hyperglycemia, and the typical effect of exercise on the user's blood glucose.
- The two steps, learning the user's response curves and suggesting the optimal insulin dose, can be decoupled. Once the time dependent response curves are calculated, they can be integrated to determine the cumulative effect of each kind of insulin and dietary carbohydrates. The insulin:carb ratio can then be calculated as the total effect of 1 unit of insulin divided by the total effect of 1 carbohydrate. Alternatively, clinically averaged response functions from many patients, in combination with the user's weight, can be used as an approximate input for the second step, determining the optimal insulin dose.
-
FIG. 1 is a flow diagram depicting the input and output to the two stages of the process of determining individualized insulin sensitivity and optimal insulin dose. - Step 1 of the method linearly regresses changes in glucose over possibly overlapping time intervals onto the following equation:
-
- where,
-
- gi is the ith glucose measure in time,
- Δgi,j=gi+j−gi,
- Δti,j=ti+j−ti
- EGP0 is endogenous glucose production extrapolated in 0 glucose, a fit parameter; p is suppression of endogenous glucose production, a fitting parameter;
- RGC=A(gi−gRGC) if g>gRGC and RGC=0 otherwise, represents renal glucose clearance where A and gRGC—the renal glucose clearance threshold—are fit parameters;
- 0short,j are responses to short-acting insulin doses Sj administered j time periods before ti, where each time period could be 30 to 60 minutes, are fit parameters;
- 0long,j are responses to long-acting insulin doses Lj administered j time periods before ti, where each time period could be 30 to 60 minutes, are fit parameters; and
- 0carb,j are responses to dietary carbohydrates Cj administered j time periods before ti, where each time period could be 15 to 60 minutes, are fit parameters.
- As another example linear-fit form, step 1 of the method could fit glucose changes to the following equation:
-
- where,
-
- Sj are doses of short-acting insulin taken within some timeframe of ti, possibly 6 hours;
- Lj are doses of long-acting insulin taken within some timeframe of ti, possibly 24 hours;
- Cj are dietary carbohydrates eaten within some timeframe of ti, possibly 3 hours; and dshort, dlong, dcarb are the degrees of polynomial response functions.
- For any linear-fit form, the length of the time periods for the response curves in step 1 is chosen such that the rate of change of glucose to that factor has an insignificant fluctuation over the time period. The number of time periods to look back from each gi—which could be different for each factor—is chosen such that the number of periods multiplied by the length of each period is longer than the time for the insulin, carbohydrate, or exercise to clear the body. Endogeneous glucose production could also be set as a separate factor for different times of day, possibly blocks of one to six hours.
- In step 2, the method could use the response functions learned in step 1 to suggest appropriate insulin doses. The output could be carbohydrate ratios, correction doses, and long-acting insulin doses for a user on MDI, or basal and bolus rates for CSII, to be programmed manually in an existing open-loop pump system or to be set automatically in a future, closed-loop artificial pancreas. The method takes the actual time series of food and exercise and combines them with the times, but not the sizes, of actual insulin doses, as well as the response functions to these factors learned in step 1. The method then calculates optimal insulin doses for each relevant event, where the ideal dose is the one that minimizes a cost function that penalizes hyperglycemia and hypoglycemia. The cost function for excursions outside the optimal glucose range could be asymmetrical in order to avoid hypoglycemia more strongly than hyperglycemia. By then averaging over dose size per carbohydrate at each meal, the method can be used to suggest a best insulin:carb ratio. Similarly, by averaging over the ideal correction dose for a given glucose level at each episode of hyperglycemia, the method can suggest the proper correction dose for different levels of hyperglycemia. Step 2 will also assume that a fixed amount of long-acting insulin is taken each day, and it can suggest its ideal dose and time of application.
- [1] JDRF, Statistics: JDRF and Diabetes, (2014)
- [2] Centers for Disease Control and Prevention, Number (in Millions) of Adults with Diabetes by Diabetes Medication Status, United States, 1997-2011, (2013)
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/577,719 US20200015760A1 (en) | 2014-11-22 | 2019-09-20 | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462083191P | 2014-11-22 | 2014-11-22 | |
US14/947,347 US10456090B2 (en) | 2014-11-22 | 2015-11-20 | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems |
US16/577,719 US20200015760A1 (en) | 2014-11-22 | 2019-09-20 | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/947,347 Continuation US10456090B2 (en) | 2014-11-22 | 2015-11-20 | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200015760A1 true US20200015760A1 (en) | 2020-01-16 |
Family
ID=56096856
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/947,347 Active 2036-06-24 US10456090B2 (en) | 2014-11-22 | 2015-11-20 | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems |
US16/577,719 Pending US20200015760A1 (en) | 2014-11-22 | 2019-09-20 | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/947,347 Active 2036-06-24 US10456090B2 (en) | 2014-11-22 | 2015-11-20 | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems |
Country Status (1)
Country | Link |
---|---|
US (2) | US10456090B2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103987321B (en) * | 2011-12-13 | 2017-06-09 | 皇家飞利浦有限公司 | For the system and method for the injectivity optimizing based on outcome quality |
US11488043B2 (en) * | 2016-05-05 | 2022-11-01 | Meta Platforms, Inc. | Systems and methods for providing data analysis based on applying regression |
MA45601A (en) * | 2016-07-08 | 2019-05-15 | Novo Nordisk As | SYSTEMS AND METHODS FOR DETERMINING SUSCEPTIBILITY TO INSULIN |
ES2903174T3 (en) | 2017-05-05 | 2022-03-31 | Lilly Co Eli | Physiological glucose closed loop monitoring |
CN107715230B (en) * | 2017-10-12 | 2019-10-01 | 微泰医疗器械(杭州)有限公司 | Insulin pump individuation configuration optimization system based on cloud big data |
US11901060B2 (en) | 2017-12-21 | 2024-02-13 | Ypsomed Ag | Closed loop control of physiological glucose |
USD889638S1 (en) | 2018-04-30 | 2020-07-07 | Bigfoot Biomedical, Inc. | Replacement cap for pen-injector device |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100262434A1 (en) * | 2007-12-13 | 2010-10-14 | Shaya Steven A | Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose |
US20140039383A1 (en) * | 2007-10-09 | 2014-02-06 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7404796B2 (en) * | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
US20080306434A1 (en) * | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
US7695434B2 (en) | 2007-10-19 | 2010-04-13 | Lifescan Scotland, Ltd. | Medical device for predicting a user's future glycemic state |
WO2010014963A2 (en) | 2008-07-31 | 2010-02-04 | Government Of The United States As Represented By The Secretary Of The Army | Universal models for predicting glucose concentration in humans |
US8762306B2 (en) | 2008-08-14 | 2014-06-24 | The University Of Toledo | Neural network for glucose therapy recommendation |
US10575791B2 (en) * | 2010-12-22 | 2020-03-03 | Roche Diabetes Care, Inc. | Automatic recognition of known patterns in physiological measurement data |
CN103959291B (en) | 2011-04-20 | 2018-05-11 | 诺沃—诺迪斯克有限公司 | Glucose predictions device based on the regularization network with adaptively selected core and regularization parameter |
US10391242B2 (en) * | 2012-06-07 | 2019-08-27 | Medtronic Minimed, Inc. | Diabetes therapy management system for recommending bolus calculator adjustments |
EP2679808A1 (en) * | 2012-06-28 | 2014-01-01 | Siemens Aktiengesellschaft | Stall detection of wind turbine blades |
WO2016061308A1 (en) * | 2014-10-17 | 2016-04-21 | Kahlbaugh Bradley E | Human metabolic condition management |
US10726030B2 (en) * | 2015-07-31 | 2020-07-28 | Splunk Inc. | Defining event subtypes using examples |
-
2015
- 2015-11-20 US US14/947,347 patent/US10456090B2/en active Active
-
2019
- 2019-09-20 US US16/577,719 patent/US20200015760A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140039383A1 (en) * | 2007-10-09 | 2014-02-06 | Dexcom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
US20100262434A1 (en) * | 2007-12-13 | 2010-10-14 | Shaya Steven A | Method and apparatus to calculate diabetic sensitivity factors affecting blood glucose |
Also Published As
Publication number | Publication date |
---|---|
US10456090B2 (en) | 2019-10-29 |
US20160162797A1 (en) | 2016-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200015760A1 (en) | Method to determine individualized insulin sensitivity and optimal insulin dose by linear regression, and related systems | |
US11679201B2 (en) | Blood glucose control system with carbohydrate therapy indication | |
CN110869075B (en) | Calculation of residual insulin Activity content in Artificial islet systems | |
EP2174128B1 (en) | Method and device for assessing carbohydrate-to-insulin ratio | |
CA2394900C (en) | Diabetes management system | |
US10369281B2 (en) | Devices, systems and methods for adjusting fluid delivery parameters | |
Turksoy et al. | Multivariable adaptive closed-loop control of an artificial pancreas without meal and activity announcement | |
US20170337348A1 (en) | Method, system and computer program product for cgm-based prevention of hypoglycemia via hypoglycemia risk assessment and smooth reduction insulin delivery | |
US7651845B2 (en) | Method and apparatus for glucose control and insulin dosing for diabetics | |
EP2171625B1 (en) | Method and device for preventing hypoglycemia | |
US20090177147A1 (en) | Insulin pump with insulin therapy coaching | |
US20120245556A1 (en) | System, Method and Computer Program Product For Adjustment of Insulin Delivery in Diabetes Using Nominal Open-Loop Profiles | |
Pinsker et al. | Evaluation of an artificial pancreas with enhanced model predictive control and a glucose prediction trust index with unannounced exercise | |
Aye et al. | Toward closing the loop: an update on insulin pumps and continuous glucose monitoring systems | |
WO2015056259A1 (en) | System and method for improved artificial pancreas management | |
Herrero et al. | Automatic adaptation of basal insulin using sensor-augmented pump therapy | |
AU2023278117A1 (en) | Method and system for determining glucose change in a subject | |
Bhat et al. | Automated glucose control: A review | |
Bando et al. | Detail glucose fluctuation and variability by continuous glucose monitoring (CGM) | |
El Fathi | Advanced Insulin Dosing Algorithms for Improving Glycemic Control in Type 1 Diabetes | |
US20220351820A1 (en) | Method for determining glucose-dependent insulin sensitivity factors | |
DO | INSULIN PUMP THERAPY FROM THE PRIMARY CARE PERSPECTIVE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIGFOOT BIOMEDICAL, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THORPE, DAYTON GRAY;LANDY, JONATHAN S.;REEL/FRAME:050448/0556 Effective date: 20180306 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: MADRYN HEALTH PARTNERS, LP, NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:BIGFOOT BIOMEDICAL, INC.;REEL/FRAME:055583/0044 Effective date: 20210312 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
AS | Assignment |
Owner name: MADRYN FUND ADMINISTRATION, LLC, NEW YORK Free format text: SECURITY INTEREST;ASSIGNOR:MADRYN HEALTH PARTNERS, LP;REEL/FRAME:062702/0145 Effective date: 20230209 |
|
AS | Assignment |
Owner name: BIGFOOT BIOMEDICAL, INC., CALIFORNIA Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:MADRYN FUND ADMINISTRATION, LLC;REEL/FRAME:062793/0316 Effective date: 20230209 |
|
AS | Assignment |
Owner name: INSULET CORPORATION, MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIGFOOT BIOMEDICAL, INC.;REEL/FRAME:062900/0001 Effective date: 20230209 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT, MARYLAND Free format text: SECURITY AGREEMENT SUPPLEMENT;ASSIGNOR:INSULET CORPORATION;REEL/FRAME:064840/0181 Effective date: 20230609 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |